189 related articles for article (PubMed ID: 9052397)
1. Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma.
Vaage J; Donovan D; Uster P; Working P
Br J Cancer; 1997; 75(4):482-6. PubMed ID: 9052397
[TBL] [Abstract][Full Text] [Related]
2. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts.
Vaage J; Barberá-Guillem E; Abra R; Huang A; Working P
Cancer; 1994 Mar; 73(5):1478-84. PubMed ID: 8111716
[TBL] [Abstract][Full Text] [Related]
3. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
Gabizon A; Martin F
Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
[TBL] [Abstract][Full Text] [Related]
4. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes.
Vaage J; Donovan D; Mayhew E; Abra R; Huang A
Cancer; 1993 Dec; 72(12):3671-5. PubMed ID: 8252484
[TBL] [Abstract][Full Text] [Related]
5. Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes.
Vaage J; Donovan D; Wipff E; Abra R; Colbern G; Uster P; Working P
Int J Cancer; 1999 Jan; 80(1):134-7. PubMed ID: 9935243
[TBL] [Abstract][Full Text] [Related]
6. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
7. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.
Goren D; Horowitz AT; Zalipsky S; Woodle MC; Yarden Y; Gabizon A
Br J Cancer; 1996 Dec; 74(11):1749-56. PubMed ID: 8956788
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of doxorubicin encapsulated in poly(ethylene glycol)-coated liposomes.
Hosoda J; Unezaki S; Maruyama K; Tsuchiya S; Iwatsuru M
Biol Pharm Bull; 1995 Sep; 18(9):1234-7. PubMed ID: 8845812
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
Parr MJ; Masin D; Cullis PR; Bally MB
J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
[TBL] [Abstract][Full Text] [Related]
10. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
[TBL] [Abstract][Full Text] [Related]
11. Ultrasound enhanced antitumor activity of liposomal doxorubicin in mice.
Hagtvet E; Evjen TJ; Olsen DR; Fossheim SL; Nilssen EA
J Drug Target; 2011 Sep; 19(8):701-8. PubMed ID: 21524240
[TBL] [Abstract][Full Text] [Related]
12. An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation.
Gokhale PC; Radhakrishnan B; Husain SR; Abernethy DR; Sacher R; Dritschilo A; Rahman A
Br J Cancer; 1996 Jul; 74(1):43-8. PubMed ID: 8679456
[TBL] [Abstract][Full Text] [Related]
13. Intracellular drug delivery by sulfatide-mediated liposomes to gliomas.
Shao K; Hou Q; Duan W; Go ML; Wong KP; Li QT
J Control Release; 2006 Oct; 115(2):150-7. PubMed ID: 16963144
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion.
Krishna R; McIntosh N; Riggs KW; Mayer LD
Clin Cancer Res; 1999 Oct; 5(10):2939-47. PubMed ID: 10537363
[TBL] [Abstract][Full Text] [Related]
15. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
16. [PEG-liposome in DDS and clinical studies].
Maruyama K
Nihon Rinsho; 1998 Mar; 56(3):632-7. PubMed ID: 9549348
[TBL] [Abstract][Full Text] [Related]
17. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes.
Harasym TO; Cullis PR; Bally MB
Cancer Chemother Pharmacol; 1997; 40(4):309-17. PubMed ID: 9225948
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
19. Development of liposomal anthracyclines: from basics to clinical applications.
Gabizon A; Goren D; Cohen R; Barenholz Y
J Control Release; 1998 Apr; 53(1-3):275-9. PubMed ID: 9741935
[TBL] [Abstract][Full Text] [Related]
20. Convection enhanced delivery of liposome encapsulated doxorubicin for brain tumour therapy.
Zhan W; Wang CH
J Control Release; 2018 Sep; 285():212-229. PubMed ID: 30009891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
